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Abstract 
BACKGROUND. Streptococcus pneumoniae is a potent human pathogen. Its pore-forming 
exotoxin pneumolysin is instrumental for breaching the host's epithelial barrier and for the 
incapacitation of the immune system.  
METHODS and RESULTS. Using a combination of life imaging and cryo-electron 
microscopy we show that pneumolysin, released by cultured bacteria, is capable of 
permeabilizing the plasmalemma of host cells. However, such permeabilization does not lead 
to cell lysis since pneumolysin is actively removed by the host cells. The process of pore 
elimination starts with the formation of pore-bearing plasmalemmal nanotubes and proceeds 
by the shedding of pores that are embedded in the membrane of released microvesicles. 
Pneumolysin prepores are likewise removed. The protein composition of the toxin-induced 
microvesicles, assessed by mass spectrometry, is suggestive of a Ca2+-triggered mechanism 
encompassing the proteins of the annexin family and members of the endosomal sorting 
complex required for transport (ESCRT) complex. 
CONCLUSIONS. S. pneumoniae releases sufficient amounts of pneumolysin to perforate the 
plasmalemma of host cells, however, the immediate cell lysis, which is frequently reported as 
a result of treatment with purified and artificially concentrated toxin, appears to be an unlikely 
event in vivo since the toxin pores are efficiently eliminated by microvesicle shedding. 
Therefore the dysregulation of cellular homeostasis occurring as a result of transient pore 
formation/elimination should be held responsible for the damaging toxin action. 
GENERAL SIGNIFICANCE. We have achieved a comprehensive view of a general plasma 
membrane repair mechanism after injury by a major bacterial toxin. 
 
Keywords: Bacterial toxin, PLY, Plasmalemmal repair, Microvesicle, Shedding, Annexin 
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1. Introduction 
Streptococcus pneumoniae is a potent human pathogen. Infection leads to common 
diseases such as otitis media, meningitis and pneumonia, which affect several million people 
and is responsible for significant infant death in developing countries [1]. The bacterial 
exotoxin pneumolysin (PLY) is instrumental for the breach of epithelial and endothelial 
barriers and the incapacitation of the host's immune system [2, 3]. 
PLY belongs to the large family of cholesterol-dependent cytolysins (CDC), toxins that are 
structurally related and characterized by their large trans-membrane pore [4]. Other prevalent 
pathogens producing CDCs are Streptococcus pyogenes (streptolysin O, SLO) and 
numerous other Gram positive bacteria, such as Clostridium, Listeria and Bacillus [5]. 
During the progress of infection PLY is released by the bacteria as soluble monomers that 
bind to cholesterol-rich microdomains within the plasma membrane of the host cells [2, 6]. 
After binding, PLY assembles in circular oligomeric prepores, undergoes a conformational 
change and perforates the plasmalemmal lipid bilayer. The formation of transmembrane 
pores leads to the loss of plasmalemmal integrity that might result in the lysis of targeted 
cells and ultimately in extended tissue damage at the site of infection and overwhelming 
immune responses [2]. 
However, plasmalemmal perforation by pore-forming toxins does not necessarily entail an 
unfavourable prognosis with respect to cellular survival. Largely depending on the 
concentration of a pore-forming toxin, the repertoire of cellular responses is considerable and 
ranges from the activation of intracellular and transmembrane signaling cascades i.e. for the 
initiation of the release of cytokines at non-lytic toxin concentrations, to imminent lytic cell 
death at lytic ones [2, 7, 8]. 
Lytic cell death has frequently been documented by using purified, concentrated exotoxins 
[2, 7]. Recently, we have shown that even at non-lytic concentrations of purified PLY the 
majority of targeted host cells are being perforated; however, these injuries are rapidly and 
efficiently resealed [9]. Ca2+-dependent recruitment of the repair machinery leads to plugging 
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of toxin pores that are either expelled into the extracellular space or internalized into the 
cellular interior [7, 10-12]. 
Here we show that during their growth bacteria produce enough PLY to perforate the plasma 
membrane of human cells. However, the host cells are capable of efficiently eliminating the 
active toxin pores and thus do not succumb to lytic death. Evaluating the mechanisms that 
are responsible for the elimination of toxin pores, we show that they are actively ejected and 
that both prepores and functional toxin pores are expelled in a Ca2+-triggered mechanism. 
Individual toxin pores and prepores have been identified by cryo-electron microscopy. Mass 
spectrometry results demonstrate that microvesicles are highly enriched in PLY, annexins, 
actin-binding and Ca2+-regulated proteins and that they also contain components of the 
ESCRT machinery. 
 
2. Materials and methods 
2.1. Mammalian cell culture and transfections 
Human embryonic kidney cells (HEK 293) and neuroblastoma SH-SY5Y cells were cultured 
as described [13]. HeLa cells were maintained in DMEM (Dulbecco`s modified Eagle`s 
medium. Gibco, Life Technologies, Paisley, UK) supplemented with 10% heat-inactivated 
FBS (Fetal Bovine Serum. Gibco, Life Technologies, Paisley, UK) and 1% penicillin-
streptomycin (Gibco, Life Technologies, Paisley, UK). Cell cultures were grown in 5% CO2 at 
37°C. Transfections were performed as described in [14]. Cells were transiently transfected 
with the coding sequence of human annexin A2, A6 or porcine annexin A1 cloned into the 
Living Colors Fluorescent protein vector pEYFP-N1 (Takara Bio Europe/Clontech, Saint-
Germain-en-Laye,  France) [14] and/or with a human charged multivesicular body protein 4B 
(Chmp4B)-mCherry construct [15]. Transfected cells were seeded on coverslips and were 
incubated for 48 h, reaching 80-90% confluence. The transfection rate for the fluorescently-
labeled constructs ranged between 70 - 90%. 
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2.2. Bacterial cultures 
The clinical pneumococcal isolates were collected in Switzerland from 1-10 year old children 
of both sexes. Strains 103.57, 211.25, 109.74, 307.14, 207.06, 208.41, 106.66, 207.31 and 
202.67 were from nasopharyngeal swabs (otitis), whereas strains B101.77, B103.21 were 
from blood cultures (septicemia). The clinical pneumococcal isolates as well as the 
pneumococcal strains D39 and PLN-A (D39 deficient in expressing PLY) were cultured in 
BHI (Brain Heart Infusion Broth, Sigma Aldrich, Buchs, Switzerland) at 37°C. The PLN-A 
strain carries an erythromycin resistance marker [16], therefore the medium was 
supplemented with 1 µg/ml erythromycin (Sigma Aldrich). For the generation of bacterial 
supernatants, bacteria grown to their stationary phase (OD500 = 1.0) were pelleted (5,000 x  
g) for 15 min. The supernatants were filtered through a syringe filter with a pore size of 0.2 
μm (VWR, Dietikon, Schweiz). Overnight cultures from D39 strain used for co-culturing 
experiments were diluted to OD500 = 0.01 in DMEM medium supplemented with 10% heat-
inactivated FBS and 20 mM HEPES (Merck, Zug, Switzerland) and grown to early stationary 
phase. For the establishment of growth curves, the overnight cultures were diluted to OD500 = 
0.01 and the OD500 was measured every 1.5 h. 
 
2.3. Recombinant toxins 
The nontoxic PLY mutant ΔA146R147 exhibits a double-amino acid deletion within the PLY 
sequence [17] and is N-terminally tagged with GFP. Recombinant PLY and EGFP-tagged 
PLY were cloned and purified as follows: all primers were synthesized by Microsynth 
(Balgach, Switzerland) and are detailed in the Supplementary File 1. Restriction enzymes 
were from Fermentas (ordering partner: Fisher Scientific, Wohlen, Switzerland) and all other 
reagents used in the cloning experiments were purchased from Promega (Dübendorf, 
Switzerland) if not otherwise stated. Isolation of the genomic DNA of the strain D39 was 
performed with the E.Z.N.A. ® Bacterial DNA Kit (VWR). The PLY gene and the EGFP gene 
(from pN1-EGFP vector; Clontech, Saint-Germain-en-Laye, France) were amplified. The 
PCR products as well as the pET28a vector were cut with the complementing restriction 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
6 
 
enzymes (BamHI, XhoI) and purified by the PCR Clean-up Kit (Qiagen, Hilden, Germany). 
First the PLY PCR product was ligated into the pET28a vector (Novagen, Madison, USA; 
digested with BamHI and XhoI). Subsequently, the EGFP PCR-product was ligated into the 
pET28a-PLY vector (digested with NheI and BamHI) by the T4-DNA ligase. Positive clones 
were sequenced. The pET28a-PLY and the pET28a-EGFP-PLY vector were transformed in 
BL21 (DE3) pLysS competent cells. Protein expression was induced with 1 mM IPTG (Sigma 
Aldrich) at the bacterial culture OD500 = 0.5 - 0.7. Bacterial cells were incubated for 4 h at 
37°C and harvested by centrifugation (5,000 x g, 4°C, 30 min). The recombinant proteins 
were purified with Protino® Ni-NTA 1 ml columns (MACHEREY-NAGEL, Oensingen, 
Switzerland) according to the manufacturer`s instructions. The protein content of the eluates 
was determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
and high protein contents were pooled. Two dialysis steps to phosphate buffered saline 
(PBS) (1 mM DTT added) were performed with a cellulose membrane tube that retains 
proteins with ≥ 12 kDa (Sigma Aldrich) according to the manufacturer`s instructions. The 
protein concentration was determined with a bicinchoninic acid (BCA) assay (Pierce™ BCA 
Protein Assay Kit, Thermo Scientific, Reinach, Switzerland) and the hemolytic activity of PLY 
as well as EGFP-PLY was assessed by a hemolysis assay. 
 
2.4. Hemolysis assay 
Human red blood cells were isolated from whole blood of healthy volunteers and were stored 
in the Alsever’s solution (Sigma Aldrich). Before each experiment red blood cell suspension 
was centrifuged (3,000 x g, 4°C, 10 min). Pelleted erythrocytes were washed twice with PBS 
(3,000 x g, 4°C, 10 min) and used as the source (100%) in the hemolysis assay. Serial 
dilutions of bacterial culture (OD500 = 1.0) supernatants or recombinant toxins, pre-activated 
with 5 mM DTT, were incubated with 1 % human red blood cells at 37°C for 60 min in PBS. 
The absorbance of the supernatant was measured at 450 nm and the hemolytic activity was 
calculated according to the formula: hemolysis (%) = ((A sample – A negative control) / (A positive control – 
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A negative control)) x 100. Negative control = 1 % human red blood cells in PBS. Positive control = 
1 % human red blood cells in H2O. 
 
2.5. Confocal microscopy 
If not otherwise stated Tyrode`s buffer (140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM 
glucose, 10 mM HEPES, pH = 7.4) containing 2.5 mM CaCl2 (calcium Tyrode`s buffer) or 
100 µM EGTA  was used in all experiments. Imaging was performed as described in [9]. In 
brief, transfected cells (~250000 cells/coverslip) were mounted in a recording perfusion 
chamber and were washed with 200 µl of Tyrode`s buffer containing calcium or EGTA. At 
time point = 0 the buffer was completely removed and the cells were treated with 200 µl of 
the indicated solutions. If mammalian cells were treated with bacterial supernatants, 100 µl of 
bacterial supernatants were diluted in 100 µl calcium Tyrode’s buffer. Co-culturing of 
mammalian cells with S. pneumoniae was performed as follows: transfected HEK 293 cells 
were grown to confluency in cell culture dishes with a glass bottom (CELLviewTM, Ø35 mm, 
Greiner Bio-one, Frickenhausen, Germany). Mammalian cells were washed with calcium 
Tyrode`s buffer, infected with 2 ml of bacterial culture (OD500 = 0.4) and monitored for 80 min 
at 37°C and 5% CO2. Fluorescence was recorded in time series for 45 min with an Axiovert 
200 M microscope equipped with a laser scanning module LSM 510 META (Zeiss) using a 
x63 oil immersion lens [18]. Annexin-A2 positive microvesicles that were released in 
individual experiments were counted manually (every 5th frame, 300 frames à 9 s) and are 
expressed as the number of microvesicles/cell/min. 
 
2.6. Isolation of PLY-induced microvesicles and total membrane isolates  
HEK 293 cells (107 cells, transfected or untransfected as indicated) were gently washed with 
PBS. Microvesicle shedding was induced by treatment with PLY or EGFP-PLY in calcium 
Tyrode`s buffer containing 5 mM DTT (2 µg/ml PLY in 2 ml total volume). If indicated, the 
unbound toxin was removed after 2.5 min and the toxin-free calcium Tyrode`s buffer was re-
added. The cells were incubated for 45 min at room temperature. The supernatant containing 
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the shed microvesicles was collected. Total membranes were isolated by detaching cells with 
a cell scraper and rigorous fragmentation (20 x) with a glass homogenizer. The supernatant 
containing shed microvesicles or the fragmented cell suspension was centrifuged two times 
at 2,100 x g for 10 min to remove cell debris and membrane material was pelleted at 130,000 
x g for 1h (90TI rotor, Optima L, Beckman Coulter, Nyon, Switzerland). The pellets were re-
suspended in calcium Tyrode`s buffer (for cryo-electron tomography) or 1 x SDS sample 
buffer for SDS-PAGE. 
 
2.7. Mass spectrometry 
The microvesicle and the total membrane pellets were subjected to SDS-PAGE (the total 
membrane isolate was loaded in x 2 serial dilutions). After Coomassie Brilliant Blue R-250 
staining (Sigma-Aldrich), the microvesicle isolate lane and the total membrane isolate lane 
containing the matching protein concentration were carefully dissected out and analyzed by 
the Mass Spectrometry and Proteomics Core Facility (PMSCF) of the Department of Clinical 
Research at the University of Bern with an ESI-LTQ-Orbitrap: The samples were reduced, 
alkylated and digested with trypsin. Each sample was loaded onto a pre-column (PepMap 
C18, 5µm, 300A, 300µm x 1.5mm length) at a flow rate of 20µL/min with solvent A (0.1% 
formic acid in water/acetonitrile 98:2). After loading, peptides were eluted in back flush mode 
onto the analytical nano-column (magic C18, 5µm, 300A, 0.075 mm i.d. x 75mm length) 
using an acetonitrile gradient of 5% to 40% solvent B (0.1% formic acid in water/acetonitrile 
4,9:95) in 60min at a flow rate of ~400nL/min. The column effluent was directly coupled to an 
LTQ-orbitrap XL mass spectrometer (ThermoFisher, Bremen, Germany) via a nano spray 
ESI source operated at 1700 V. Data acquisition was made in data dependent mode with 
precursor ion scans recorded in the Fourier transform detector (FT) with resolution of 60’000 
(@ m/z =400) parallel to five fragment spectra of the most intense precursor ions in the linear 
iontrap. CID mode settings were: Wideband activation on; precursor ion selection between 
m/z range 360-1400; intensity threshold at 500; precursors excluded for 15 sec. CID spectra 
interpretation was performed with EASYPROT on a local, multicore processor server run 
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under linux. A small database containing all UniProt database: uniprot_sprot; taxonomies: 
1313, 9606. The following variable modifications were used: carboamidomethylated Cys (no 
limit), Met oxidation (limited to 1), Asn/Gln deamidation. 2. Parent and fragment mass 
tolerances were set to 10 ppm and 0.6 Da, respectively.  
All peptides identifications with a score of >4 were accepted for peptide mapping. The protein 
match score summation (PMSS) was used for relative quantification [19]. The PMSS adds up 
all scores from peptide spectral matches to one particular protein irrespective of whether a 
peptide was identified several times, with or without modifications. 
 
2.8. Immunoblotting / amido black staining 
The pellet of microvesicles as well as the total membrane pellet (in x 2 serial dilutions) was 
applied to SDS-PAGE. Immunoblotting was performed with a polyvinylidene difluoride 
(PVDF) membrane (Millipore AG, Zug, Switzerland) and a mouse monoclonal antibody 
against annexin A2 (#A14020, BD Biosciences, Allschwil, Switzerland), annexin A6 
(#610067, BD Biosciences, Allschwil, Switzerland) and heat shock protein 90 (Hsp90) 
(#SMC-149 A/B, StressMarq Biosciences Inc., Victoria, Canada). All 1st antibodies were 
diluted 1:500. The horseradish peroxidase (HRP)-linked ECL 2nd antibody was diluted 1:1000 
(#NA931-1ML, GE healthcare, Little Chalfont, UK). The membrane was developed with 
WesternBright ECL (Advansta, Menlo Park, USA) and the band intensities were analyzed by 
FIJI [20]. After immunoblotting, the membrane was stained with amido black and the relative 
total protein content in the microvesicle sample was determined by matching to serial 
dilutions of the total membrane isolates. In addition, the protein concentration of the 
microvesicle isolate and the total membrane isolate was determined by a BCA assay. 
 
2.9. Fluorescence activated cell sorting (FACS) analysis 
PLY or EGFP-PLY induced microvesicles shed from either annexin A2-mCherry or non-
transfected HEK 293 were isolated by centrifugation as described above and re-suspended 
in equal volumes for FACS analysis (400 µl). For FM1-43 (SynaptoGreen C4, Biotium, 
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Hayward, USA) staining the microvesicles were incubated with 12.3 µg/ml dye. The mixture 
was shortly vortexed, incubated for 10 min and directly subjected to FACS measurement. 
Microvesicles were analyzed with a LSRII (BD Instruments, San Jose, USA). The settings 
and compensations were set according to microvesicles from non-transfected cells induced 
by PLY, non-transfected cells induced by PLY-EGFP, and annexin A2-mCherry transfected 
cells with PLY. Data acquisition was performed with constant sample flow rate and was 
analyzed with FlowJo software (FlowJo, LLC, Ashland, USA). Data acquisition was 
performed with constant sample flow rate and was analyzed with FlowJo software (FlowJo, 
LLC, Ashland, USA). 
 
2.10. Immunogold labeling and conventional electron microscopy 
The supernatant of PLY-challenged HEK 293 cells was centrifuged two times at 2100 x g for 
10 min and filtrered (syringe filter, PFTE membrane, pore size 0.45 µm, Millex, Millipore). 
The membrane was removed from the plastic housing, cut into individual segments and 
incubated with a mouse monoclonal antibody against PLY (PLY-4, 1:50; Abcam, Cambridge, 
UK), washed with Tyrode`s buffer containing 2.5mM Ca2+ followed by incubation with an IgG 
goat anti-mouse 10 nm gold 2nd antibody (1:100; Sigma-Aldrich). The membrane was frozen 
at high pressure (210 MPa, EMPACT instrument, Leica-Microsystems, Vienna, Austria), 
cooled down to -196 °C and freeze-substituted as described previously in [21]. Ultrathin 
sections were viewed with a Philips CM12 transmission electron microscope and images 
were recorded with the Olympus analySIS software (Olympus, Volketswil, Switzerland). 
 
2.11. Cryo-electron tomography 
Isolated microvesicles were mixed with 10 nm fiducial gold solution (#s10110/8, AURION 
Immuno Gold Reagents & Accessories, Wageningen, The Netherlands). The mixture was 
applied to a 200 mesh lacey carbon film grid (#AGS166-3, Agar Scientific, Elektron 
Technology UK Ltd, Stansted, UK). Excess liquid on the grid was removed by blotting with a 
filter paper and the grid was immediately plunge frozen in liquid ethane with a homebuilt 
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plunge freezer. The grid was mounted on a cryo-holder (Gatan, Pleasonton, CA, USA) and 
transferred to a Tecnai F20 transmission electron microscope (FEI, Eindhoven, The 
Netherlands), set to low dose conditions, operated at 200 kV, and equipped with a field 
emission gun. Images were recorded with a 2k x 2k charge-coupled device (CCD) camera 
(Gatan) mounted after a GIF Tridiem post-column filter (Gatan) operated in zero-loss mode. 
The sample was kept at about -180°C. Tilt series were acquired using SerialEM  for 
automated acquisition recorded typically from -60° to 60° with a 2° angular increment. 
Defocus was set to -8 µm and the total electron dose used was about 90 e-/Å2. Image 
processing was done in IMOD [22]. The alignments were done using the automated fiducial 
tracking function and the 3D reconstructions were done using the weighted back projection 
followed by a nonlinear anisotropic diffusion (NAD) filtering. 
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3. Results 
3.1. Plasmalemmal repair in host cells damaged by S. pneumoniae 
In nucleated cells, PLY-induced plasmalemmal perforations lead to a pore-induced entry of 
extracellular Ca2+ [14]. As a result, fluorescently-labelled annexin A2 (used as an intrinsic 
Ca2+ sensor [14]) translocated from the cytoplasm to the plasma membrane (Supplementary 
Figure 1A, B, cells marked by stars, Video 1, 2). Ongoing plasmalemmal repair and the 
elimination of  PLY-pores manifested themselves by annexin A2 back-translocation to the 
cytosol as a result of plasmalemmal resealing and the restoration of [Ca2+]i to its resting 
levels by the cellular Ca2+-sequestration machinery [9] (Supplementary Figure 1A, Video 1). 
Failure to reseal the damaged plasmalemma led to lysis of the affected cells [9, 18]. 
Equilibration between extracellular (~2.5 mM) and intracellular (~100 nM) [Ca2+] resulted in 
stable elevation of [Ca2+]i  followed by the permanent association of annexin A2, with the 
plasmalemma and, at a later stage, also with intracellular membranes (Supplementary Figure 
1B, Video 2). Supplementary Figure 1 and Videos 1 and 2 show results of experiments 
performed in HEK 293 cells that were treated with a S. pneumoniae bacterial culture 
supernatant; similar results were obtained with purified PLY [9] and SLO [13]. Identical 
responses to permeabilization by pore-forming toxins were observed in primary human 
airway epithelial cells (AEC), human neuroblastoma SH-SY5Y cells and human bronchial 
epithelial cells (HBE) [9, 13]. This suggests that the elimination of toxin-induced pores is a 
general cellular defense mechanism which is independent of cell- or toxin type. 
In order to ascertain PLY concentrations ([PLY]) that are required for the perforation/lysis of 
nucleated cells, monolayers (80-90 % confluence) of epithelial (HEK 293) or mesenchymal 
(SH-SY5Y) cells, expressing annexin A2-YFP, were treated with varying amounts of purified 
PLY. Infrequent plasmalemmal perforations were registered already at [PLY] = 50 ng/ml (~1 
nM) (not shown); at 250 ng/ml [PLY] ~30% of cells, and at 1 µg/ml [PLY] ~60% of cells were 
permeabilized (Figure 1). No differences in the extent of plasmalemmal perforation were 
observed between HEK 293 and SH-SY5Y cells (Figure 1). 
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Figure 1: Permeabilization and lysis of nucleated cells by purified PLY. 
HEK 293 cells (red lines) or SY5Y cells (blue lines) were treated with different [PLY]. The 
percentage of cells showing plasmalemmal perforation (circles) and lysis (squares) are 
plotted. The 1 µg/ml point corresponds to 87 hemolytic units. Mean ± SD, N ≥ 6; 
 
Nucleated cells have developed the means of repairing pore-induced plasmalemmal lesions 
([7]; Supplementary Figure 1A, Video 1). Hence, in comparison to their degree of 
plasmalemmal perforations, much higher [PLY] (≥ 2 µg/ml) were required to induce cell lysis 
(Figure 1). There was no difference in the extent of PLY-induced lysis between HEK 293 and 
SH-SY5Y cells (Figure 1). 
In order to ascertain whether [PLY] that are required for the perforation/lysis of nucleated 
cells can be reached in pneumococcal cultures, i.e. at conditions that are likely to occur in 
vivo, [PLY] were estimated in 11 clinically isolated S. pneumoniae strains and in the D39 
laboratory strain by comparing their hemolytic activity with that of purified PLY of known 
concentration (Table 1). Two of the tested strains showed no hemolytic activities, which 
suggests that these strains do not express/release PLY. Among the hemolytically active 
strains, [PLY] in the bacterial culture supernatants ranged from 200 ng/ml to 800 ng/ml. 
Notably, whereas all hemolytically active strains produced PLY at concentrations that were 
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sufficient to permeabilize nucleated cells, none of the strains seem to release enough PLY to 
induce lysis of the cells as judged from indirect comparison of data obtained in hemolysis 
assay (Table 1) and in experiments performed in nucleated cells (Figure 1). 
 
Table1: Concentration of PLY in S. pneumoniae strains. [PLY] released by 12 S. 
pneumoniae strains were determined by comparing the hemolytic activities of bacterial 
culture supernatants with that of purified PLY of known concentration. One hemolytic unit will 
cause 50% lysis of 1% red blood cell suspension in phosphate buffered saline, pH 7.4, after 
incubation at 37 °C for 60 min. Mean ± SD, N = 6. 
 
S. pneumoniae 
(strain) 
[PLY] 
(µg/ml) 
Hemolytic activity 
(Units/ml) 
103.57 (nasopharyngeal swab) 0.799 ± 101 333 
211.25 (nasopharyngeal swab) 0.641 ± 181 263 
109.74 (nasopharyngeal swab) 0.629 ± 169 262 
307.14 (nasopharyngeal swab) 0.439 ± 86 200 
207.06 (nasopharyngeal swab) 0.419 ± 81 175 
208.41 (nasopharyngeal swab) 0.371 ± 185 156 
106.66 (nasopharyngeal swab) 0.343 ± 66 143 
B101.77 (blood culture) 0.248 ± 14 103 
D39  0.217 ± 28 90 
207.31 (nasopharyngeal swab) 0.199 ± 36 83 
B103.21 (blood culture) 0 0 
202.67 (nasopharyngeal swab) 0 0 
  (Units/mg) 
Purified PLY 4000 435000 
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Purified eGFP-PLY 2000 250000 
 
In order to address the permeabilization/cytolytic activities of pneumococcal culture 
supernatants directly in nucleated cells, HEK 293 and SH-SY5Y cells expressing annexin 
A2-YFP were treated with bacteria-free culture supernatants obtained from S. pneumoniae 
D39 or S. pneumoniae 103.57  strains. D39 was among the strains that released the lowest 
amount of PLY, whereas 103.57 released the highest amount of PLY (Table 1). 
Pneumococci predominantly release PLY when they reach the stationary phase of growth 
and undergo autolysis [23, 24]. At these conditions (stationary phase; OD500=1.0) the 
perforation of nucleated cells was minimal for the D39 bacterial strain (HEK 293 cells: 8% ± 
5% SD, total of 107 cells recorded in 4 separate experiments; SH-SY5Y cells: 8% ± 8% SD 
(total of 70 cells recorded in 3 separate experiments) and no lysis of either HEK 293 or SH-
SY5Y cells was observed. 
In order to ensure that PLY activity was not lost during the preparation of bacterial culture 
supernatants, we performed co-culture experiments, in which D39 bacteria grown to late-
exponential-phase in DMEM cell culture medium (OD500=0.4), were directly applied to HEK 
293 cells and were further co-incubated with the cells for 80 minutes reaching the stationary 
phase of growth (OD500=0.5, Supplementary Figure 2). Comparable to the experiments with 
bacteria-free culture supernatants, 8% ± 8% SD of cells (total of 215 cells recorded in 5 
separate experiments) experienced plasmalemmal perforations during co-culturing with D39 
bacteria; all were able to reseal their PLY-damaged plasmalemma (Video 3). 
Next, we treated nucleated cells with the bacterial culture supernatant obtained from S. 
pneumoniae 103.57 strain, which was the most hemolytically active one among all bacterial 
strains that were tested in this study (Table 1). Even at these experimental conditions only 
49% ± 10% SD of HEK 293 cells (220 cells in 5 separate experiments) were permeabilized, 
and a mere 2% ± 3% SD succumbed to PLY-induced lysis. Similar results were obtained with 
SH-SY5Y cells: 43% ± 20% SD of cells treated with the 103.57 supernatant (total of 112 cells 
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recorded in 5 separate experiments) experienced plasmalemmal perforations; all perforated 
cells were able to reseal. 
 
Despite its prominent binding to the plasmalemma, the inactive fluorescently-labelled PLY 
mutant ΔA146R147 [17] did not trigger plasmalemmal perforations in HEK 293 cells as 
judged by the absence of annexin A2 translocations (Video 4). Likewise, stationary, PLY-
deficient PLN-A bacteria, in which PLY is genetically disrupted were unable to induce 
annexin A2 translocations [16] (Video 5). 
Taken together, these experiments suggest that in vivo, pneumococci are able to produce 
sufficient PLY to perforate the plasmalemma of host cells; however the cells possess 
adequate means to repair such plasmalemmal injuries - at least at the initial stage of 
pneumococcal infection. 
 
3.2. Mechanisms of plasmalemmal repair: annexin- and PLY-containing microvesicles are 
shed by cells treated with S. pneumoniae 
We have shown that members of the annexin protein family are instrumental in the repair of 
toxin-induced pores [7, 25]. By translocating to the perforated plasma membrane the 
annexins plug the pores that are subsequently expelled into the extracellular space [9, 13, 
21]. Accordingly, the plasmalemma of nucleated cells treated with S. pneumoniae 103.57  
culture supernatants (Figure 2A, B) or with sub-lytic concentrations of purified PLY (Figure 
2C) sprouts thin, annexin A2-YFP positive "nanotubes" (Figure 2 arrows) that appear to 
break down by releasing microvesicular material into the extracellular milieu (Figure 2 
arrowheads, Video 1). The annexin A2 plugs are marked by stars (Figure 2 B; C). Likewise, 
protrusions were generated and microvesicles were released by HEK 293 cells after ~ 60 
minutes of co-culturing with S. pneumoniae D39 (Video 3) or after treatment with sub-lytic 
[PLY] (Video 6). 
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Figure 2: PLY-induced formation of nanotubes and release of microvesicles in HEK 293 and 
SH-SY5Y cells. The 103.57 pneumococcal supernatant (67 hemolytic units) initiates 
sprouting of thin nanotubes from the plasma membrane of HEK 293 (A, arrows) or of SH-
SY5Y (B, arrows) cells. Their breakdown is followed by the ejection of microvesicles 
(arrowheads). Purified PLY (2 µg/ml; 174 hemolytic units) also induces nanotube formation, 
which is accompanied by the subsequent release of microvesicular material (C). 
Representative images are shown. N = 5. Min:sec = time after treatment with the bacterial 
supernatant. Scale bars = 10 µm 
  
Released microvesicles contained membrane-associated annexins but were completely 
devoid of cytosolic proteins (Figure 3, Video 6), which suggests that the formation of an 
outward plasmalemmal fold composed of two tightly associated lipid bilayers is involved in 
shedding of the toxin. 
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Figure 3: Annexin-rich microvesicles are devoid of cytosolic CFP. Sub-lytic [PLY] (2 µg/ml; 
174 hemolytic units) induce the release of annexin A6 containing microvesicles (upper panel, 
examples are highlighted by yellow arrowheads) in HEK 293 cells expressing annexin A6-
YFP and cytosolic CFP. Similar results were obtained also for other annexins (annexin A2 
and annexin A1). However, the shed microvesicles do not contain CFP (lower panel). N = 3. 
Representative images are shown. Min:sec = time after treatment. Scale bar = 10 µm. 
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For the unequivocal detection of PLY on the plasma membrane we generated hemolytically 
active, N-terminally EGFP-tagged PLY. The labelled toxin enabled us to observe the 
formation of nanotubes and the release of microvesicles that contained both annexin A2 and 
PLY (Figure 4). 
 
 
 
Figure 4: Formation of nanotubes and release of microvesicles visualized with EGFP-PLY.  
Annexin A2-mCherry-expressing SH-SY5Y (A) or HEK 293 (B) were treated with 2 µg/ml 
EGFP-PLY (100 hemolytic units). EGFP-PLY rapidly binds to the plasma membrane and 
initiates the formation of nanotubes with the toxin capping their tips (arrows) and the release 
of microvesicles (arrowheads). N = 4. Representative images are shown. Min:sec = time 
after treatment. Scale bars = 10 µm. 
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FACS analysis of microvesicles isolated from annexin A2-mCherry transfected HEK 293 cells 
confirmed the co-localization of EGFP-PLY with the annexin (Supplementary Figure 3). 
Despite a caveat of underrepresenting a population of microvesicles that were smaller than 
500 nm, these data corroborate our imaging results (Figure 4) and are consistent with our 
previous suggestion that the removal of PLY pores from the plasmalemma during repair 
occurs by a process of annexin-mediated plugging and shedding [13, 21]. 
 
 
The presence of PLY on shed microvesicles was additionally confirmed by immunogold 
labelling with toxin-specific antibodies (Supplementary Figure 4). 
The internalization of toxin pores following lysosome-plasmalemma fusion constitutes an 
alternative mechanism for repair of toxin-damaged plasmalemmal regions [26]. However, we 
were unable to detect an internalization of EGFP-tagged PLY in SH-SY5Y or HEK 293 cells 
either at sub-lytic [PLY] (Figure 4) or at lytic [PLY] (Supplementary Figure 5). 
 
Toxin-induced nanotube formation in artificial membranes [27] and the formation of SLO-
containing ectosomes/blebs in PFA-fixed cells [28] suggest that plasmalemmal tubulation 
and shedding might occur spontaneously, as a result of an intrinsic lipid rearrangement 
within the toxin-targeted plasmalemmal lipid-bilayer. Those studies imply that shedding 
follows in a protein-independent manner and therefore also occurs in lysed cells. However, 
our results indicate that microvesicles are preferentially shed at sub-lytic [PLY] by actively 
repairing cells: a peak of microvesicle release was observed at 2 µg/ml PLY (Figure 5) - at 
conditions when ~70% of the cells were permeabilized but successfully resealed their 
plasmalemma and only ~ 5% were undergoing lytic degradation (Figure 1, Video 7; [9]). 
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Figure 5: Microvesicles are predominantly shed at sub-lytic PLY concentrations. HEK 293 
cells expressing fluorescently-labeled annexin A2 were exposed to different [PLY]. At sub-
lytic [PLY] = 2 µg/ml the highest amount of annexin-enriched microvesicles was released 
compared to lower [PLY] = 0.25 - 1 µg/ml or higher [PLY] = 4 - 8 µg/ml (blue circles). The 
chelation of extracellular Ca2+ completely inhibited microvesicle release (red squares). The 1 
µg/ml point corresponds to 87 hemolytic units. For any experimental condition N ≥ 6; mean ± 
SEM. 
 
At higher [PLY], at conditions under which the majority of cells succumbed to PLY-induced 
lysis, microvesicle release was significantly diminished (Figure 5, Video 8). This suggests 
that only the living, but not the lysed cells, were able to undergo PLY-induced microvesicle-
driven repair. Correspondingly, the chelation of extracellular Ca2+, which leads to increased 
cell lysis due to the ineffectiveness of Ca2+-dependent repair [9] prevented the shedding of 
microvesicles (Figure 5). 
Components of the ESCRT machinery have recently been reported to mediate the shedding 
of toxin-perforated membrane sites in HeLa cells [15]. In particular Chmp4B and the ATPase 
Vps4 (vacuolar protein sorting 4) have been proposed indispensable for the Ca2+-dependent 
evagination and scission of wounded membranes as microvesicles [15]. We did not observe 
the association of Chmp4B with the plasmalemma of PLY-perforated cells, in contrast to the 
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PLY-induced translocation of annexin A2 (Supplementary Figure 6). However, in our 
experiments we failed to achieve cytosolic localization of Chmp4B, which was reported in 
[15], either in HEK 293, in SH-SY5Y or even in HeLa cells that were used in [15] 
(Supplementary Figure 6), which might be the reason for the discrepancy between the two 
data sets. 
 
3.3. PLY prepores and pores are actively released within the shed microvesicles 
Our imaging experiments (Figures 2 - 4) suggest that released microvesicles are smaller 
than 1 µM in diameter. In addition, a release of larger vesicles, some of them in the form of 
plasmalemmal blebs, can be expected after toxin-induced, self-inflicted mechanical damage 
[13]. This process is documented in Supplementary Figure 7 (Video 9), which shows a PLY-
perforated cell, whose appendage initially sprouts multiple blebs and is afterwards destroyed 
by its own contraction. Likewise, shedding of SLO-pores within rather larger plasmalemmal 
blebs/ectosomes has previously been invoked as a plasmalemmal repair mechanism [28]. 
 
Cryo-electron microscopy of plunge-frozen material, which was released by cells treated with 
sub-lytic [PLY] demonstrated that the population of released vesicles was highly 
heterogeneous, ranging from 45 nm to 1560 nm (Figure 6). However, more than 90% of the 
vesicles were smaller than 500 nm (median = 163 nm, 176 vesicles, Figure 6), suggesting 
that the contribution of larger vesicles in the shedding of PLY-pores was negligible. Whereas 
no quantitative analysis of size distribution was provided in [28], the reported SLO-induced 
blebs/ectosomes were heterogeneous in size, ranging from 200 nm to 2 µm, which is similar 
to the size distribution, observed in the present study. 
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Figure 6: PLY-induced microvesicles visualized by cryo-EM. Sub-lytic [PLY] (2 µg/ml; 174 
hemolytic units) induce the release of microvesicles (A). The microvesicle population is 
heterogeneous and exhibits PLY structures bound to the membranes visible as top views 
(pink arrow) and side views (yellow arrow). High density material is frequently located under 
PLY structures (blue arrows). Some PLY structures associate back-to-back (upper yellow 
arrow). (B) A microvesicle (red square) released by cells that were not incubated with PLY. 
Only four vesicles were found on the entire EM grid (compared to ~ 10000 in case of toxin-
treated cells). Inset: magnified view of the vesicle. Asterisks: ice contamination. Arrowheads: 
fiducial gold beads. (C) The diameters of the microvesicles were measured in cryo-maps and 
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the frequency of different sizes is given in percent. The majority of microvesicles are smaller 
than 500 nm. N= 3. Scale bars = 100 nm. 
 
Cryo-electron tomography of plunge-frozen microvesicles was further used to identify active 
pores within a population of PLY that also includes prepores and PLY monomers. The side 
views of PLY oligomers illustrate prepores with an intact plasma membrane underneath 
(Figure 7A) as well as functional pores featuring a perforated membrane (Figure 7B). The top 
view of oligomeric PLY does not allow the discrimination between prepore and functional 
pore due to the inferior resolution along the Z-axis, characteristic of electron microscopic 
tomography (Figure 7C). 
 
 
Figure 7: PLY oligomers are present in the membranes of microvesicles released by HEK 
293 cells. Sub-lytic [PLY] (2 µg/ml; 174 hemolytic units) induce the release of microvesicles. 
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(A) PLY prepore with an intact membrane underneath the ring structure (arrow). (B) The PLY 
pore depicts a ruptured membrane (arrow); the pore is fused back-to-back to a prepore. (C) 
Top view of an assembled PLY structure. Scale bars = 50 nm. (D) The diameters of PLY-ring 
structures were measured in 22 tomograms. Top views (54), prepore side views (17), pore 
side views (7) and back-to-back structures of prepores (85) and pores (23) do not show 
significant differences in their ring diameters. 
 
The diameters analyzed from the side views of prepores yield sizes in the range of 27.2 to 
36.5 nm (30.0 nm ± 2.1 SD), which is similar to the size of functional pores that exhibit 
diameters of 25.8 - 37.7 nm (31.4 nm ± 4.2 SD) and to the diameters established in top views 
(21.2 - 35.2 nm; 30.0 nm ± 2.7 SD) (Figure 7D). Microvesicles are often fused by a back-to-
back assembly of prepores or pores (Figure 7B), analogous to earlier reports using artificial 
liposomes [29]. 
The detection of PLY in microvesicles does not necessarily denote active toxin removal by 
the cell, since binding and oligomerization of PLY monomers can also occur after the 
microvesicles have been shed. In order to ascertain that the toxin was actively eliminated 
from the plasma membrane of host cells, we pre-incubated annexin A2-mCherry transfected 
cells with EGFP-PLY for 2.5 min which was followed by 45 min incubation in a PLY-free 
buffer and the isolation of microvesicles. FACS analysis revealed a population of PLY-
negative, annexin-positive microvesicles in addition to microvesicles containing both PLY 
and the annexin (Figure 8A). The PLY-positive vesicles presumably originate from the tips of 
the nanotubes depicted in Figure 4 and constitute original sites of PLY-pore assembly 
around which the initial plasmalemmal evagination occurs. The PLY negative vesicles 
presumably originate from the nanotube stalks (Figure 4). Cryo-electron microscopic 
tomograms of microvesicles that were generated in these experiments after the unbound 
toxin had been removed confirms the presence of PLY pores and prepores in the membrane 
of shed microvesicles (Figure 8B). Quantification of the number of PLY oligomeric structures 
on PLY-containing microvesicles revealed an average of 21 structures per µm2, which is 
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similar to the density of SLO-pores on blebs reported in [28], however, in contrast to the latter 
the pore:prepore ratio was estimated at 1:9. 
 
 
Figure 8: PLY structures are actively removed from the plasma membrane of host cells. HEK 
293 cells expressing annexin A2-mCherry were treated with [EGFP-PLY] = 2 µg/ml (100 
hemolytic units). The unbound toxin was removed after 2.5 min and cells were further 
incubated for 45 min.(A) FACS analysis of the released microvesicles revealed the presence 
of microvesicles containing both annexin A2 and PLY (15% ± 7% SD) as well as annexin-
positive, PLY-negative (22% ± 9% SD) and a few annexin-negative, PLY-positive (1% ± 
0.4% SD) microvesicles. N = 3. Data from an individual experiment with 90% transfection 
efficiency are shown. (B) Cryo-electron tomograms illustrate the presence of PLY prepores 
(right side) and pores (left side) in the membranes of the microvesicles. N= 5. Scale bar = 
50 nm 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
27 
 
 
3.4. PLY-induced microvesicles carry a complex protein cargo 
In order to identify proteins that were specifically enriched in the PLY-released microvesicles 
and, therefore might play a role in plasmalemmal repair, we compared the protein 
composition of the microvesicles with that of the total cellular membrane preparations, which 
contained components originating from both the plasma membrane as well as from the 
intracellular membranes. The latter preparation was selected as a reference since 
microvesicles are expected to originate from plasmalemmal folds that are devoid of cytosolic 
components and also the intracellular membranes (e.g. lysosomes [26]) are expected to play 
a role in the process of plasmalemmal repair. Analysis of the total protein concentration 
revealed that 8% ± 4% SD (N = 6) of total membrane protein mass was emitted as 
microvesicular protein cargo at sub-lytic [PLY]. Western blot analyses of individual proteins 
demonstrated that 5% ± 5% SD (N = 4) of membrane-associated Hsp90 was expelled with 
microvesicles, which is comparable to the amount of total protein released with microvesicles 
and, thus suggests its random and equal distribution on the plasmalemma and on the 
released microvesicles (Supplementary Figure 8). However, 33% ± 22% SD (N = 6) of 
membrane-associated annexin A6 (~4-fold enrichment compared to the released total protein 
mass (~8%)) and 22% ± 20% SD (N = 5) of membrane-associated annexin A2 (~2-3-fold 
enrichment) were detected in the microvesicular fraction, which is indicative of their specific 
accumulation within microvesicles (Supplementary Figure 8). 
Mass spectrometric analysis of the protein composition of PLY-released microvesicles and of 
purified total membranes (3 independent experiments) yielded 1073 proteins in the 
microvesicle fraction compared to 1036 in the total membrane isolate. This is a very sensitive 
method, therefore it is only to be expected that many of these proteins are contaminants. 
These could originate from the cytosol and the intracellular compartments of cells that were 
lysed by PLY or during experimental handling or might belong to the content of broken (and 
vesiculated) cellular protrusions depicted in Supplementary Figure 7. In total, 190 proteins 
were enriched in the microvesicle fraction compared to the fraction of total cellular 
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membranes in all 3 experiments (Supplementary File 2). We are aware that the total 
membrane fraction or any other isolate are not a precise match for the microvesicles and 
therefore do not consider enrichment per se as a well-defined indicator of a selective 
presence of a particular protein within the microvesicle fraction. Hence we applied a more 
stringent criterion of at least 4-fold enrichment in all 3 experiments, which yielded 38 proteins 
(Table 2). Prominent members of these were annexins A6, A7 and A11 together with several 
other Ca2+-sensing proteins, actin-binding proteins, components of the ESCRT-I complex 
and proteins that are involved in the intracellular vesicle trafficking (Table 2). 
 
Table 2: Mass spectrometric analysis of isolated microvesicles. Proteins with an at least four-
fold increased PMSS index in microvesicles compared to total membrane isolates in all 
individual experiments are listed (HEK 293 cells; N = 3). 
Pneumolysin 
Ca
2+
-dependent or Ca
2+
-regulated: 
Annexin A6  
Annexin A7  
Annexin A11  
Calcyclin-binding protein 
Calpain-1 catalytic subunit 
Nucleobindin-1 
Peflin 
Tumor protein D52 
Actin-binding: 
 Calponin-3 
Plastin-2 
Plastin-3 
Transgelin-2 
Unconventional myosin-Ic 
Vesicular trafficking/ESCRT-components: 
ADP-ribosylation factor-like protein 1 
Flotillin-2 
GTP-binding protein SAR1a 
Programmed cell death 6-interacting protein 
Syntenin-1  
Tumor susceptibility gene 101 protein 
Unconventional myosin-Ic 
Unconventional myosin-Id 
Ubiquitin fusion degradation protein 1 homolog 
Vacuolar protein sorting-associated protein 28 homolog 
Heat shock protein-/chaperone-associated: 
DnaJ homolog subfamily B member 1 
DnaJ homolog subfamily A member 2 
DnaJ homolog subfamily C member 7 
Prefoldin subunit 5 
Stress-induced-phosphoprotein 1 
Enzymes: 
Casein kinase II subunit alpha' 
Malate dehydrogenase, mitochondrial  
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Peroxiredoxin-2 
Pyruvate kinase isozymes M1/M2 
Thioredoxin-dependent peroxide reductase, mitochondrial 
Tetraspanin-/Immunoglobulin super family-associated: 
CD9 antigen  
Immunoglobulin superfamily member 8 
Junctional adhesion molecule A 
Prostaglandin F2 receptor negative regulator 
RNA-associated: 
Eukaryotic translation initiation factor 4 gamma 2 
Eukaryotic translation initiation factor 5A-1 
Far upstream element-binding protein 1 
Far upstream element-binding protein 2 
Others: 
Integrin alpha-5 light chain 
Monocarboxylate transporter 1 
Suppressor of G2 allele of SKP1 homolog 
Synapse-associated protein 1 
 
 
4. Discussion 
4.1. Repair of plasmalemmal toxin pores is critical for the cellular response to early 
pneumococcal invasion 
Pneumolysin (PLY) is the most prevalent virulence factor of Streptococcus pneumoniae. Its 
assembly into large transmembrane pores leads to perforation of the plasmalemma of the 
host cells, which might result in immediate lysis. Our data suggest that during pneumococcal 
infection PLY is released in amounts that are sufficient to permeabilize host cells. In general, 
cells are capable of repairing the PLY-induced plasmalemmal lesions. Their ability to 
withstand low amounts of PLY is crucial for the course of infection since “non-lytic” [PLY] 
trigger the release of pro-inflammatory cytokines and the recruitment of immune cells [30-32]. 
Our data suggest that PLY-induced activation of cellular signaling can occur even without a 
specific receptor and it appears to be a result of successful repair of the PLY-perforated 
plasmalemma since the effective plasmalemmal repair in perforated cells is accompanied by 
transient elevation in [Ca2+]i [9, 13, 18, 21, 33], which is a major second messenger. On the 
other hand, dysregulation of cellular homeostasis occurring as a result of transient, pore-
induced entry of calcium ions might be responsible for the long-term damaging toxin action 
since high [Ca2+]i is a potent activator of apoptosis. 
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4.2. Microvesicle release is the membrane repair strategy of choice 
The fact that several, seemingly mutually excluding mechanisms have been advocated for 
plasmalemmal repair of toxin-perforated cells, rev. by [7, 25, 34, 35] points to its critical 
importance for cellular survival. It is likely that the repair strategy of choice depends as much 
on the nature and the extent of the damage, as on the metabolic status of damaged cells and 
even on their geometry [13]. 
In either case, toxin-perforation leads to Ca2+-influx and subsequently to the mobilization of 
the Ca2+-dependent plasma membrane repair machinery [25] which attempts to immediately 
neutralize the injury in order to prevent noxious Ca2+-flooding and to restore plasma 
membrane integrity [9, 18, 21, 33]. We have shown that after perforation, Ca2+-dependent 
members of the annexin protein family are recruited to the plasma membrane [9, 18, 21, 36] 
resealing the sites of excessive Ca2+-influx and allowing the cell to quarantine the damaged 
membrane regions [13, 18, 21, 33]. The annexin-driven plugging of the initial toxin-induced 
plasmalemmal perforations is crucial: plasmalemmal repair is severely compromised in cells 
in which expression of either annexin A1 or annexin A6 was down-regulated [21, 33]. There 
is also sufficient evidence that the plasmalemmal repair mechanisms described here in 
molecular detail are not restricted to the toxin-induced perforations [37] and are also 
operative in vivo [25]. In particular annexin A1 has been implicated in epithelial repair of 
inflamed stomach and colon [38, 39], while annexin A5 is upregulated in neurons and glia in 
rats after experimental spinal cord trauma [40]. 
The plugged toxin pores are removed by shedding of the affected regions into the 
extracellular milieu in the form of microvesicles/ectosomes [13, 18, 21]. Ectosomal, 
microvesicular structures are credited with clinical importance since they do not only act as 
biomarkers but are also implicated in short and long distance intercellular communication 
[41-43]. An alternative route for the removal of toxin pores is represented by intracellular 
uptake, following pore-induced fusion of lysosomes with the damaged plasmalemma, as has 
previously been shown for the elimination of SLO pores [26]. 
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Here we show that microvesicular release is associated with the formation of thin nanotubes 
that originate on the plasmalemma of cells treated with S. pneumoniae and that appear to 
break down by releasing microvesicular material into the extracellular milieu. Released 
microvesicles were relatively small (median = 163 nm) with more than 90% of them being 
smaller than 500 nm. Larger PLY-containing vesicles observed in this study or SLO-
containing blebs that were reported earlier [28] might be a sub-product of nanotube-induced 
microvesicle shedding; otherwise they might originate from the heavily damaged cells [13]. 
It is conceivable that the release of microvesicles occurs spontaneously since nanotubes that 
sprout from toxin-attacked cells are so thin that they might break off passively, either by 
Brownian motion or by shear stress. Toxin-induced blebbing in chemically fixed cells [28] has 
previously been taken as evidence for spontaneous plasmalemmal resealing which is driven 
by rearrangement of the plasmalemmal lipid-bilayer. We have addressed the possibility of 
passive microvesicle shedding, exclusively driven by the physical action of the toxin on the 
membrane rather than by the active contribution of cellular proteins [28] but we were unable 
to affirm the presence of this particular mechanism. 
On the other hand, active modes of microvesicle formation cannot be excluded. Annexins 
possess membrane fusogenic activity, and thus might be responsible for microvesicle 
release [25, 44], or else the shedding of toxin-perforated membrane sites is mediated by 
components of the ESCRT-III complex (Chmp4B, Vps4; [15]). A Ca2+-dependent 
accumulation of components of the ESCRT-III complex has previously been shown to be 
followed by outward budding and scission of the damaged sites in plasmalemmal repair of 
laser- and toxin induced cellular injuries [15]. This study [15] did not find evidence for a 
contribution of annexin A1 in membrane repair, which might indicate that the injury model 
described by Jimenez et al. (2014) [15] did not induce sufficient Ca2+-influx for the 
recruitment of annexin A1 to the perforated plasmalemmal sites (20 µM is required for 
annexin A1) [9]. However, the presence of more sensitive annexins such as A2, A6 or A11 
was not investigated and thus cannot be excluded. Although we failed to observe an 
association of Chmp4B with the plasmalemma of PLY-perforated cells, we found that the 
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ESCRT-I components Tsg101 and Vps28 were highly enriched in the preparations of purified 
shed microvesicles. 
 
4.3. PLY pores within released microvesicles structurally resemble those in artificial 
membranes 
PLY prepore and pore structures in artificial liposomes are well characterized by cryo-
electron microscopy [29]. In addition, the packing of monomers in the prepore complex has 
been described by crystallography [45]. The plasma membrane of living cells differs from 
artificial liposomes as regards lipid composition, the presence of an extracellular matrix, 
peripheral and integral membrane proteins and, importantly, by its ability to actively react to a 
toxin-attack. Yet, the diameters of toxin pores in sample preparations of PLY-containing 
microvesicles are only slightly different than the ones that have been described in artificial 
liposome membranes [29]. 
 
4.4. Microvesicles are selectively enriched in proteins instigating membrane repair and 
vesicular trafficking 
The mass spectrometric analysis of the PLY-induced microvesicle isolate yields a complex 
protein cargo with annexins among the most prevalent proteins, further supporting their 
active role in plasmalemmal repair. We found that other Ca2+-regulated proteins, such as 
peflin and the calpain 1 catalytic subunit are highly enriched in microvesicles. The 
enrichment in the microvesicular fraction of several actin-binding proteins (transgelin 2, 
myosin Ic) is in line with the contribution of the actin cortex in plasmalemmal resealing [13, 
33, 34]. The apoptosis-linked gene 2 (ALG-2) and ALIX (ALG-2 interacting protein X) have 
been described to direct ESCRT-III proteins to the perforated sites in a Ca2+-dependent 
manner [15]. It is interesting to note that ALG-2 has been reported to interact with N-terminal 
Pro-rich regions of annexin A7 and A11 [46, 47], suggestive of a potential link between the 
annexin family and the ESCRT complex. Interestingly, cryo-electron tomography showed that 
high density material was frequently locally concentrated within microvesicles under PLY 
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structures. In all likelihood, this material corresponds to the proteins detected by mass 
spectrometry. In particular, the accumulation of the annexins directly at the damaged sites of 
plasmalemma ([9, 21]; Figure 2) is well documented and the formation of two-dimensional 
annexin A5 arrays at the sites of plasmalemmal injury has been recently reported [37]. 
 
5. Conclusions 
S. pneumoniae releases sufficient PLY for toxin-induced plasmalemmal perforation in host 
cells, however, at least in the initial stages of infection, repair mechanisms are highly 
effective. Therefore, an immediate and straightforward cell lysis, which is frequently reported 
in the literature as a result of treatment with purified and artificially concentrated toxins, 
appears to be an unlikely event in vivo. Our data suggest that it is rather the dysregulation of 
cellular homeostasis occurring as a result of transient, pore-induced entry of second-
messenger calcium ions that should be held responsible for the damaging toxin action. We 
present evidence that active microvesicle shedding is the predominant mechanism of toxin 
removal and that PLY is not internalized or shed in a passive process. Detailing the structure 
of PLY-oligomers on biological membranes, we demonstrate that prepores and functional 
pores are likewise removed. The protein composition of the toxin-induced vesicles is 
suggestive of a Ca2+-triggered mechanisms involving the annexin protein family and 
members of the ESCRT complex. 
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Highlights 
S. pneumoniae releases sufficient PLY to perforate host cells. 
PLY-induced plasmalemmal perforations are efficiently repaired. 
Microvesicle shedding is the predominant mechanism of PLY-pore elimination.  
PLY prepores are likewise removed.  
Shed microvesicles are enriched in annexins and ESCRT proteins. 
